Urs Kerkmann

853 total citations · 1 hit paper
23 papers, 547 citations indexed

About

Urs Kerkmann is a scholar working on Dermatology, Rheumatology and Physiology. According to data from OpenAlex, Urs Kerkmann has authored 23 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Dermatology, 6 papers in Rheumatology and 6 papers in Physiology. Recurrent topics in Urs Kerkmann's work include Dermatology and Skin Diseases (13 papers), Asthma and respiratory diseases (5 papers) and Hair Growth and Disorders (4 papers). Urs Kerkmann is often cited by papers focused on Dermatology and Skin Diseases (13 papers), Asthma and respiratory diseases (5 papers) and Hair Growth and Disorders (4 papers). Urs Kerkmann collaborates with scholars based in Germany, United States and United Kingdom. Urs Kerkmann's co-authors include Marianne Placzek, Bernhard Przybilla, Kristian Reich, Klaus-Peter Gilbertz, Thomas Herzinger, Ekkehard Haen, Howard Sofen, Andrew Blauvelt, Marco DiBonaventura and Claire Clibborn and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and Journal of Investigative Dermatology.

In The Last Decade

Urs Kerkmann

22 papers receiving 525 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

2022 134 citations Kristian Reich, Jacob P. Thyssen et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Urs Kerkmann Germany	12	364	230	131	116	70	23	547
C. Pickard United Kingdom	10	195 0.5×	225 1.0×	109 0.8×	90 0.8×	92 1.3×	15	589
Anna Chiara Fostini Italy	7	188 0.5×	204 0.9×	67 0.5×	45 0.4×	45 0.6×	7	356
Bo Ri Kim South Korea	12	251 0.7×	204 0.9×	109 0.8×	31 0.3×	101 1.4×	74	625
M Mattii Italy	10	356 1.0×	278 1.2×	30 0.2×	67 0.6×	34 0.5×	13	528
Narumol Silpa‐archa Thailand	15	208 0.6×	198 0.9×	105 0.8×	25 0.2×	55 0.8×	46	461
James Tarbox United States	8	299 0.8×	108 0.5×	90 0.7×	190 1.6×	35 0.5×	20	465
Eva‐B. Bröcker Germany	7	362 1.0×	245 1.1×	77 0.6×	273 2.4×	30 0.4×	7	803
Henz Germany	6	86 0.2×	166 0.7×	67 0.5×	96 0.8×	30 0.4×	6	312
Anna Michalak-Stoma Poland	12	223 0.6×	458 2.0×	90 0.7×	11 0.1×	54 0.8×	26	620
Alan Clucas France	10	373 1.0×	61 0.3×	69 0.5×	138 1.2×	9 0.1×	13	476

Countries citing papers authored by Urs Kerkmann

Since Specialization

Citations

This map shows the geographic impact of Urs Kerkmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Urs Kerkmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Urs Kerkmann more than expected).

Fields of papers citing papers by Urs Kerkmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Urs Kerkmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Urs Kerkmann. The network helps show where Urs Kerkmann may publish in the future.

Co-authorship network of co-authors of Urs Kerkmann

This figure shows the co-authorship network connecting the top 25 collaborators of Urs Kerkmann. A scholar is included among the top collaborators of Urs Kerkmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Urs Kerkmann. Urs Kerkmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gooderham, Melinda, Marjolein de Bruin‐Weller, Stephan Weidinger, et al.. (2024). Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations. Dermatology and Therapy. 14(8). 2285–2296. 3 indexed citations

Silverberg, Jonathan I., et al.. (2024). 50865 Efficacy of Step-up Abrocitinib Treatment in Combination With Topical Medicated Therapy for Treating Atopic Dermatitis Flares: A Post Hoc Analysis of the JADE REGIMEN Trial. Journal of the American Academy of Dermatology. 91(3). AB38–AB38.

Mesinkovska, Natasha Atanaskova, Brett King, Xingqi Zhang, et al.. (2024). Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis. The Journal of Dermatology. 51(11). 1414–1424. 2 indexed citations

Wollenberg, Andreas, et al.. (2023). A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. 37(10). 2041–2046. 8 indexed citations

Reich, Kristian, Jonathan I. Silverberg, Kim Papp, et al.. (2023). Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study. Journal of the European Academy of Dermatology and Venereology. 37(10). 2056–2066. 20 indexed citations

Guttman‐Yassky, Emma, Paola Facheris, Ester Del Duca, et al.. (2023). Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis. Allergy. 79(5). 1258–1270. 17 indexed citations

King, Brett, Paradi Mirmirani, Kristen Lo Sicco, et al.. (2023). LB1697 Individual SALT score trajectories of de novo patients with alopecia areata (AA) treated with ritlecitinib in the ongoing phase 3, long-term, open-label ALLEGRO-LT study. Journal of Investigative Dermatology. 143(9). B15–B15. 2 indexed citations

King, Brett, Paradi Mirmirani, Kristen Lo Sicco, et al.. (2023). 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies. Journal of Investigative Dermatology. 143(11). S344–S344. 2 indexed citations

Silverberg, Jonathan I., J. Mark Jackson, Robert S. Kirsner, et al.. (2023). Narrative Review of the Pathogenesis of Stasis Dermatitis: An Inflammatory Skin Manifestation of Venous Hypertension. Dermatology and Therapy. 13(4). 935–950. 7 indexed citations

10.

Reich, Kristian, Jacob P. Thyssen, Andrew Blauvelt, et al.. (2022). Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. The Lancet. 400(10348). 273–282. 134 indexed citations breakdown →

11.

Kim, Brian, Jonathan I. Silverberg, Sonja Ständer, et al.. (2021). Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies. Dermatitis. 32(1S). S39–S44. 11 indexed citations

12.

Bruin‐Weller, Marjolein de, Andrew Pink, Annalisa Patrizi, et al.. (2019). 161 EUROSTAD Prospective Observational Study: Baseline Characteristics, Atopic Dermatitis Severity, and Patient-Reported Outcomes. Journal of Investigative Dermatology. 139(9). S241–S241. 1 indexed citations

13.

Combe, Bernard, Frank Behrens, Neil McHugh, et al.. (2016). Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials. The Journal of Rheumatology. 43(6). 1063–1067. 23 indexed citations

14.

Gallo, Gaia, et al.. (2016). Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage. RMD Open. 2(1). e000186–e000186. 11 indexed citations

15.

Rich, Phoebe, Marc Bourcier, Howard Sofen, et al.. (2013). Ustekinumab improves nail disease in patients with moderate‐to‐severe psoriasis: results from PHOENIX 1. British Journal of Dermatology. 170(2). 398–407. 79 indexed citations

16.

Gottlieb, Alice B., Robert E. Kalb, Andrew Blauvelt, et al.. (2011). The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study. Journal of the American Academy of Dermatology. 67(4). 642–650. 45 indexed citations

17.

Reich, Kristian, Jean-Paul Ortonne, Urs Kerkmann, et al.. (2010). Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial. Dermatology. 221(2). 172–178. 46 indexed citations

18.

Placzek, Marianne, et al.. (2007). Effect of ultraviolet (UV) A, UVB or ionizing radiation on the cell cycle of human melanoma cells. British Journal of Dermatology. 156(5). 843–847. 20 indexed citations

19.

Placzek, Marianne, Urs Kerkmann, Klaus-Peter Gilbertz, et al.. (2005). Ultraviolet B-Induced DNA Damage in Human Epidermis Is Modified by the Antioxidants Ascorbic Acid and D-α-Tocopherol. Journal of Investigative Dermatology. 124(2). 304–307. 81 indexed citations

20.

Placzek, Marianne, Urs Kerkmann, S A Bell, Peter Koepke, & Bernhard Przybilla. (2004). Tobacco smoke is phototoxic. British Journal of Dermatology. 150(5). 991–993. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact